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Abstract
Background: Increasing access to and targeting of artemisinin-based combination therapy (ACT) is a key component
of malaria control programmes. To maximize efficacy of ACT and ensure adequate treatment outcomes, patient and
caregiver adherence to treatment guidelines is essential. This review summarizes the current evidence base on ACT
adherence, including definitions, measurement methods, and associated factors.
Methods: A systematic search of the published literature was undertaken in November 2012 and updated in
April 2013. Bibliographies of manuscripts were also searched and additional references identified. Studies were
included if they involved at least one form of ACT and reported an adherence measurement.
Results: The search yielded 1,412 records, 37 of which were found to measure adherence to ACT. Methods to
measure adherence focused on self-report, pill counts and bioassays with varying definitions for adherence.
Most studies only reported whether medication regimens were completed, but did not assess how the treatment
was taken by the patient (i.e. timing, frequency and dose). Adherence data were available for four different ACT
formulations: artemether-lumefantrine (AL) (range 39-100%), amodiaquine plus artesunate (AQ + AS) (range 48-94%),
artesunate plus sulphadoxine-pyrimethamine (AS + SP) (range 39-75%) and artesunate plus mefloquine (AS + MQ)
(range 77-95%). Association between demographic factors, such as age, gender, education and socio-economic status
and adherence to ACT regimens was not consistent. Some evidence of positive association between adherence and
patient age, caregiver education levels, drug preferences, health worker instructions, patient/caregiver knowledge and
drug packaging were also observed.
Conclusions: This review highlights the weak evidence base on ACT adherence. Results suggest that ACT adherence
levels varied substantially between study populations, but comparison between studies was challenging due to
differences in study design, definitions, and methods used to measure adherence. Standardising methodologies for
both self-report and bioassays used for evaluating adherence of different formulations across diverse contexts would
improve the evidence base on ACT adherence and effectiveness; namely, specific and measurable definitions for
adherence are needed for both methodologies. Additionally, further studies of the individual factors and barriers
associated with non-adherence to ACT are needed in order to make informed policy choices and to improve
the delivery of effective malaria treatment.
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Background
Despite increased support for malaria control over the
past decade, the malaria burden remains high in many
endemic countries, particularly in sub-Saharan Africa
[1]. Prompt treatment with artemisinin-based combin-
ation therapy (ACT) targeted towards those confirmed
to have malaria is a key malaria control strategy [2,3].
In 2003, less than twenty countries had adopted ACT
as the first-line treatment for uncomplicated malaria
[4,5]. With the support of donors, specifically the Global
Fund to Fight Aids, Tuberculosis and Malaria (GFATM)
and the President’s Malaria Initiative (PMI), the number
of countries that have deployed ACT has increased dra-
matically, allowing for treatment to be more widely
available [5]. By 2010, 84 countries had adopted ACT,
with 60 countries providing ACT free-of-charge to all
ages in the public sector and eight have piloted the
provision of subsidized ACT in the private sector through
the Affordable Medicines Facility – malaria (AMFm)
[2,6,7]. Changing anti-malarial treatment policy to ACT is
not enough to ensure proper treatment of malaria. Ad-
dressing access and targeting of these efficacious treat-
ments is necessary [8], recognizing that improving access
to effective drugs does not guarantee patient acceptability
and ultimately adherence to the medications [9].
The pathway to treatment effectiveness includes a
number of factors, each of which contributes to the
overall success of an intervention (Figure 1). Each step
can independently and collectively impact the overall ef-
fectiveness of an anti-malarial treatment regimen. Fac-
tors related to poor patient acceptance and adherence
not only threaten individual outcomes (recovery), but
may lead to higher treatment costs (retreatment) and
even resistance [10].
Focusing on the health system challenges to improving
access and targeting without addressing factors deter-
mining adherence, may ultimately lead to suboptimal
health outcomes. Given that resistance to artemisinin
compounds has been reported in Southeast Asia [11],
and the growing concerns about the spread of resistance
and how to contain it, ensuring provider compliance
and patient/caregiver adherence to treatment guidelines
is even more important.
Strategies that address ‘therapy-related’ factors [12],
such as co-packaging anti-malarials into blister packs,
have been shown to improve adherence, and reduce
the practice of using mono-therapies [9,13,14]. While
co-packaging anti-malarial combinations ensures dis-
pensing the correct combination of drugs, it does not
reduce the total number of tablets or the frequency the
drugs need to be taken. In addition, co-packaging
does not necessarily change patient perception or tol-
erability of individual drugs, and patients may choose
to take only one of the medications or not all of the
tablets [15-17].
In an effort to overcome the limitations of co-packaged
anti-malarial drugs and to improve adherence, several
artemisinin-based combinations have been co-formulated;
the most common of these are artemether–lumefantrine
(AL) and the new co-formulated versions of amodiaquine-
artesunate (AQAS) and artesunate-mefloquine (ASMQ).
Measuring adherence to medications
Despite the large evidence base on adherence to treat-
ment for both chronic and acute disease, no gold stand-
ard has been clearly established for measuring patient
adherence to medications [18,19]. Adherence can be
measured both directly and indirectly. The four most
common methods for measuring adherence are: (i) elec-
tronic monitoring devices such as the medical event
monitoring system (MEMS), (ii) pill counts, (iii) self-
report through interviews; and (iv) biological assays
[18-22]. Additionally, adherence to medications can be
measured by reviewing medical records, patient diaries
or by directly observing drug intake (as is often the case
for drug efficacy studies).
The default gold standard for measuring medication
adherence has been MEMS [18,23]. MEMS containers
collect data on the frequency and timing of when the
medication container was opened. Traditionally pill
counts in the context of chronic disease occurred
when patients came back to the health worker and the
Figure 1 Treatment effectiveness pathway. This figure depicts
each step along the pathway to malaria treatment effectiveness. At
the top of the pathway are the health system factors such as
choosing efficacious treatments such as ACT, improving access to
those treatments and targeting treatments to those that need it
most. The second half of the pathway depicts individual factors that
can enhance or disrupt the effectiveness pathway such as provider
compliance to treatment guidelines and patient/caregiver
adherence to treatment regimens. Source: Original figure courtesy of
Marcel Tanner, personal communication 2012 and manuscript
published by, The malERA Consultative Group on Health Systems
and Operational Research, A Research Agenda for Malaria
Eradication: Health Systems and Operational Research. PLoS Med,
2011. 8(1): p. E1000397.
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health worker ‘counted’ the number of remaining tab-
lets thus determining whether the patient was adherent
to the treatment protocol [22]. Enumerating the quantity
of remaining tablets is rarely used alone, but usually in
combination with patient interviews or self-reports. Al-
though MEMS has been adopted as the gold standard for
adherence to medications administered for chronic dis-
ease, it is not optimal for monitoring adherence to anti-
malarial medications.
Bio-assays look at the levels of drug or their metabo-
lites in a biological sample (usually blood or urine) taken
from the patient shortly after they have taken their med-
ications. Although this can provide a direct method of
measuring whether a medication was ingested, such as-
says can be costly and are dependent on the availability
of laboratory testing and thus are impractical in resource
limited settings.
Thus, although a variety of methods have been applied
to measure medication adherence, each method has both
advantages and disadvantages. Therefore, no clear gold
standard exists for measuring adherence for treatment
of acute diseases (like malaria).
Adherence to anti-malarial drugs
In 2005, Yeung and White produced a comprehensive
review of 24 studies on how anti-malarials were used by
patients [10]. As this review was undertaken in the in-
fancy of the ACT era, two studies looked at artemisinin
monotherapy treatments [24,25] and six studies looked
at ACT; four in Asia [26-29] and two in Africa [30,31].
Only one study carried out in Uganda looked at a co-
formulated ACT (AL) [31]. Results for adherence varied
for ACT, ranging from 78% for a three-day regimen of
AS + SP in Zambia [30] to maximum of 93% for AL in
Uganda [31]. Adherence was found to be generally better
when “interventions focusing on provider knowledge
and behaviour, packaging and provision of correct dos-
age” were implemented [10].
Since 2005, ACT, and in particular co-formulated ver-
sions of ACT have been scaled up across Africa. How-
ever, despite the key role adherence plays in treatment
effectiveness, the evidence on adherence to ACT in op-
erational settings is limited. In order to summarize the
current evidence base on ACT adherence, a systematic
review of current peer-reviewed literature was under-
taken. In addition, the methods to measure adherence,
definitions of adherence, and factors affecting adherence
to ACT were also examined.
Methods
Search strategy
A systematic search of the published literature was
undertaken in November 2012 and updated in April
2013. Three databases (Medline, Embase and Global
Health) were searched using predefined search terms
(see Additional file 1: Literature Review Search Strategy).
References were imported into the electronic reference
manager Endnote and duplicates removed. Bibliograph-
ies of manuscripts were searched and additional relevant
references identified and, where appropriate, included in
the review.
Titles and abstracts were screened for relevance
based on the inclusion/exclusion criteria. Studies that
reported adherence to malaria treatment were retained
for further review. The full texts of the remaining stud-
ies were read by two different reviewers to ensure they
met the inclusion criteria and to improve the quality of
the data extracted. Studies were included if they in-
volved at least one ACT, had primary or secondary data
on adherence, were found in a peer reviewed journal, writ-
ten in English, and published after 1990 and up to April
2013. We included any study that reported measuring ad-
herence and/or levels of adherence to ACT, including ef-
fectiveness trials that had measured adherence as a
secondary outcome.
Data extraction and presentation
An electronic matrix was developed in Microsoft Excel
prior to the full text review with predetermined charac-
teristics. Studies were evaluated using quality measures
adapted from the Critical Appraisal Skills Programme
(CASP) [32], STROBE [33,34] and the CONSORT guide-
lines [35] to facilitate a comparison of quality across
studies (see Additional file 2: Quality Assessment of
Studies). Studies were independently assessed and infor-
mation extracted by two reviewers and the findings were
compared and compiled. A third reviewer settled any
discordance between the initial two reviewers. Due to a
lack of homogeneity among the studies a meta-analysis
of the adherence data was not possible. This review pro-
vides a description of the study characteristics, methods
and their findings presented by drug combination and
study design.
Results
The search yielded 1,412 records, 424 of which were
duplicate records and were subsequently removed
(Figure 2). The titles and abstracts of the remaining
records (988) were screened and 42 articles were
found to be eligible for a full-text review. An add-
itional nine studies were identified from the reference
lists and were also included in the review. From the
review of the full-text versions of the 51 articles, 14
studies were found to not meet the inclusion criteria.
The search yielded 37 articles that evaluated patient
adherence to ACT, which were subsequently reviewed
and summarized.
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Definitions used for ACT adherence
The definition of patient adherence was not stan-
dardized across studies, however the majority used a
variation of the same definitions first used by Depoortere
and Fogg [30,31], and defined adherent patients/caregivers
as those who reported to have taken the treatment as rec-
ommended (in terms of timing and dosage) with no tab-
lets remaining. In the instance where the packaging was
not available the patients were classified as probably
adherent.
Twenty-nine studies reported whether patients/caregivers
took/administered all of the prescribed medication (using
pill count, self-report or both methods), but did not report
exactly how the medication was taken (i.e. timing, fre-
quency and dose). Twelve of those studies expanded this
definition of adherence and also investigated both the dur-
ation and timing of each dose in order to determine
whether the drug was taken as recommended, but these
were limited to studies investigating AL [36-47]. Some
therapeutic effectiveness studies measured drug metabolites
to determine if a treatment had been taken, thus the defin-
ition of adherence was only based on the presence or levels
of drug metabolites in the blood [27,48].
Methods of measuring ACT adherence
All four methods commonly used to measure adherence to
medications were used to measure ACT adherence. Self-
report from patients/caregivers alone [39-41,46,49-54] or
in combination with pill counts was found to be the pri-
mary method of assessing adherence to ACT treatment
[30,31,36-38,42-45,47,48,55-65]. Only one study in Ghana
reported using self-report alone [66].
A single study in Malawi reported using MEMS to
measure ACT adherence [67]. The use of MEMS was lim-
ited to a subset of patients and was subject to availability
of the bottles. This measurement was used in combination
with patient questionnaires and biological assays. Patients
self-reported 100% adherence to AL, but with the MEMS
only 92% were found to be adherent, suggesting that self-
report might overestimate adherence.
Figure 2 Systematic review process. Flow diagram (adapted from PRISMA) describing the systematic review of the literature on ACT adherence.
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Eight studies reported using biological assay methods,
including five that evaluated lumefantrine blood concen-
trations [31,45,46,67,68] and three in which bio-assays
were used for studies involving AS +MQ and compara-
tor drugs [26,27,50]. Five of the studies used bioassay in
combination with self-report [31,46,50,67,68].
Adherence to ACT
Artemether-lumefantrine
Almost half of the studies (17) looked at patient adherence
to AL (Table 1), fourteen of which were conducted in East
or Southern Africa [30,31,36-38,43,44,46,49,51,57,63,64,68].
Only one study was conducted in West Africa (Ghana)
within a study looking at the feasibility of Home Manage-
ment of Malaria [42]. Two studies were conducted in Asia,
one in Myanmar [47] and the other in Bangladesh [45].
Levels of adherence for AL ranged from as low as
38.7% in Ethiopia [43] to 96.0% in South Africa [49]. Of
the 17 studies evaluating AL, two used cross-sectional
household surveys [49,69], three were randomized
controlled trials [45,57,64], two were pre-post inter-
vention designs [42,51] and 10 used a prospective ob-
servational design [31,36-38,43,44,47,58,63,68]. The two
cross-sectional studies, one conducted in South Africa
Table 1 Studies that measure adherence to AL
Study design Study
author
Country Study
year
Population Sample
size
Measurement method Adherence
Cross-sectional Barnes [49] South Africa 2002 All ages 239 Self-report 96.0%
Simba [46] Tanzania 2008 3-59mo 467 Bioassay (blood levels)
plus self-report
88.3%
Prospective
observational
Depoortere [58] South
Sudan
2002 6-59mo 107 Pill counts & self -report
(questionnaire)
59.1%
Fogg [31] Uganda 2002 <5 yrs 5-14 yrs
15 + yrs
210 Pill counts & self-report
(questionnaire) & bioassay
90.0%
Ngasala [68] Tanzania 2007 3-59mo 177 Bioassay (D7 lumefantrine
levels)
37%
Kabanywanyi
[36]
Tanzania 2008 <13 yrs 13 + yrs 552 Pill counts & self -report
(questionnaire)
89.2%
Lemma [43] Ethiopia 2008 >2mo 180 Pill counts & self -report
(questionnaire)
38.7%
Mace [38] Malawi 2009 6-59mo 5-17 yrs
18 + yrs
868 Pill counts & self -report
(questionnaire)
65.0%
Ogolla [44] Kenya 2009 12-59mo 73 Pill counts & self -report
(questionnaire)
75.8%
Lawford [37] Kenya 2009 <15 yrs 15 + yrs 918 Pill counts & self -report
(questionnaire)
64.1%
Kalyango [63] Uganda 2011 4-59mo 1256 Pill counts & self -report
(questionnaire)
99.2% (I)iii
98.5% (C)
Zaw Win [47] Myanmar 2012iv All ages 248 Pill counts & self -report
(questionnaire)
89.5%
Pre-post intervention
study
Chinbuah [42] Ghana 2004/
2005
6-59mo 363 Pill counts & self -report
(questionnaire)
92.5%v
Kangwana [51] Kenya 2008/
2009
3-59mo 3,288b;
3,182a
Self-report 53.1% Before 67.0%
Aftervi
RCT Mubi [64] Tanzania 2006 All ages 2156 Pill counts & self -report
(questionnaire)
99.3% CDvii
97.4% RDT
Rahman [45] Bangladesh 2006/
2007
>2 yrs 320 Pill counts & self -report
(questionnaire) & bioassay
93.1%viii
Cohen [57] Uganda 2009 All ages 395 Pill count or Self-report 65.8%
iSelf-report only. The lumefantrine levels were not found to be significantly different between those that adhered vs. those that did not adhere.
iiBased on a cut-off of 280 ng/ml. Only 37% had > 280 ng/ml.
iii(I) = intervention and (C) = combination.
ivYear published.
vAlthough described as a pre-post intervention study, adherence data was only provided for the post-intervention phase.
viNumbers presented are for the Intervention group. The control group was 40.5% before/49.4% after. There was no significant difference found between the two
groups during the post survey.
viiCD = Clinical Diagnosis Group; RDT = Rapid Diagnostic Test Group.
viiiNon-Directly Observed Treatment.
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and another in Tanzania found adherence rates to be
96.0% and 88.3% respectively [49,69]. A RCT in Tanzania
and another RCT in Bangladesh, both found adherence
levels for AL to be greater than 90% [45,64]. In a third
RCT in Uganda, patients were blinded to potential follow-
up, and adherence was found to be only 65.8% [57]. Pre-
post intervention designs were used in Ghana and Kenya
with varying adherence rates post intervention (92.5% vs.
67.0% respectively) [42,51].
Despite similarities in measurement methods and con-
texts for the ten prospective observational studies, ad-
herence measurements were inconsistent [31,36-38,43,
44,47,58,63,68]. Ngasala et al. found adherence to be as
low 37% in Tanzania using blood lumefantrine levels
[68] and Lemma et al. in Ethiopia found similar results
(38.7%) using self-report and pill counts [43]. On the
upper end of the spectrum adherence levels measured as
high as 98.5% in Uganda and 89.5% in Myanmar both of
which used self-report and pill counts [47,63].
Two studies presented day-7 lumefantrine levels to valid-
ate AL intake and correlate with treatment outcomes
[67,68]. Bell et al. found the median day-7 lumefantrine
level to be 214 ng/ml, higher than their reference value
(<175 ng/ml) for adequate treatment [67]. However, 4/167
samples were found to have below the lower limit of quan-
tification for the assay and were exclude, but this was
not linked by the authors to non-adherence. Ngasala
et al. also reported median day-7 lumefantrine levels
(205 ng/ml), but used a <280 ng/ml as the reference
cut-off level and did not correlate lumefantrine levels
with adherence [68].
Two additional studies compared lumefantrine blood
levels between patients that had adhered to treatment and
those that were considered non-adherent. In Uganda, day-3
lumefantrine levels in patients were 3.19 μg/ml in adherent
compared 2.76 μg/ml in non-adherent patients, but the dif-
ference was not found to be statistically significant (p =
0.46) due to the limited sample size for the non-adherent
group [31]. Simba et al. also found no significant difference
(p-value not reported) in median blood lumefantrine con-
centrations on day-7 in patients that adhered (286 nmol/l)
compared to those that did not adhere (261 nmol/l) [46].
A study in Bangladesh assessed day-7 lumefantrine
levels for both validating AL intake and to compare ad-
herence to non-adherence. Lumefantrine concentrations
were not found to be different between patients receiv-
ing directly observed treatment (DOT) (860 ng/ml) ver-
sus patients with non-directly observed treatment
(NDOT) (671 ng/ml) (p = 0.56) [45]. Furthermore, blood
concentrations were also not significantly lower on day 7
in patients that did not adhere to treatment (680 ng/ml)
compared to those that had adhered (626 ng/ml) (p =
0.31), as a result of the small number in the non-
adherent group.
Amodiaquine plus artesunate
The combination amodiaquine plus artesunate (AQ +
AS) was investigated in seven studies (Tables 2 and 3)
[39,40,56,60,61,65,66]. Reported adherence varied, with a
minimum of 48% in Sierra Leone [61] to a maximum of
93% in Ghana [40]. Only two studies (one in Benin and
one in Madagascar) have evaluated co-formulated AQAS
and the reported adherence was 91% and 83%, respect-
ively [60,65].
Other combinations studied
The remaining formulations of ACT, including AS + SP,
AS +MQ, dihydroartemisinin-piperaquine (DHA-PQ) and
dispersible AL, have been investigated infrequently. Two
studies looked at the combination AS + SP (Table 4); one
study found adherence to be only 34% [30], while the other
study found adherence to be twice as high at 75% [57]. In
Asia, five studies reported on adherence to co-packaged
AS +MQ (Table 5), with adherence reported to be >90% in
four of them [26,27,50,52], while the fifth study conducted
in Cambodia found adherence levels to be only 77% [27].
Two additional studies looked at adherence to ACT in
general (Table 6) and found adherence rates to be less than
50% [48,53]. There were no studies found that presented
adherence data on the recently released co-formulated ver-
sion of ASMQ or DHA-PQ.
Comparative studies/multiple combinations
Seven studies compared AL to at least one other ACT or
anti-malarial combination (Table 3) [39-41,55,59,60,67]. In
Uganda, mean adherence to AL was 10% higher than the
mean found for quinine (95% vs. 85%; p = 0.0008) [55].
In the Gambia, adherence to AL was lower than that
of chlorproguanil-dapsone (CPD) (67% versus 94%;
p = <0.001), however no association was found between
adherence and treatment outcome for either drug [59].
In Malawi, adherence to AL was similarly compared to
SP; self-reported adherence to AL or SP were both ≥
99% and adherence as measured by MEMS was 92%
vs. 90% [67]. Three studies compared AL to AQ + AS
[39,40,60]. Faucher et al. directly compared the two
combinations in Benin, and found adherence levels for
co-formulated AQAS were higher (91%) than those of
AL (83%), but the difference was not found to be sig-
nificant (p = 0.16) [60].
Reasons for non-adherence
Although reasons for non-adherence were not reported
for all studies, there were similar trends found across the
8 studies that did report reasons for non-adherence.
Four studies reported that one reason for non-adherence
was that the mother/caregiver forgot to give the medica-
tion [43,58,59,63]. Three studies found that the caregiver
did not understand the instructions [58,59] or gave the
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wrong dose of medication by giving two doses at once
[44]. The limited availability of food/drink or a fatty
meal/food was cited for both AL and AQ +AS as rea-
sons for non-adherence [58,61,63]. In two studies, care-
givers reported that their child was still sick after the
first dose or did not improve, so the medication (AL or
AQ +AS) was discontinued [43,61]. In contrast, two
other studies found that the reason for non-adherence
was due to the fact that the patient improved and medi-
cation was discontinued [44,63].
Furthermore, sharing or saving medications was
found to be a reason for non-adherence in Ethiopia
and Kenya [43,44]. In Ethiopia, Lemma et al. reported
that patients were non-adherent to AL due to charac-
teristics of the medication such as too many tablets,
tablets were too big or bitter or that children refused
to take the medication [43]. In Kenya, Ogolloa et al.
cited that children did not like AL and were thus non-
adherent [44] and Lawford et al. reported dislike for the
medication as the reason for non-adherence [37]. Two
other studies found similar findings and cited vomiting
as the reason for non-adherence in children who took
AQ + AS in Sierra Leone [61] and those who took AL in
Uganda [63].
Table 2 Studies that measure adherence to AQ + AS
Study design Study author Country Study year Population Sample size Measurement method Adherence
Cross-sectional Beer [56] Zanzibar 2006/2007 <5 210 Pill counts & self–report
(questionnaire)
77.0%*
Prospective
observational
Gerstl [61] Sierra Leone 2008 All patients≥ 1 year 118 Pill counts & self-report
(questionnaire)
48.3%
Ratsimbasoa [65] Madagascar 2008/2009 <5 543 Self-report 90.0%**
RCT Asante [66] Ghana 2009* 15+ 401 Pill counts 95.7% (S)***
92.6% (U)
*Range 29-100%.
**Amodiaquine-artesunate co-formulated/fixed-dose combination.
***(S) = supervised; (U) = unsupervised.
Table 3 Studies that measure adherence as comparative studies
Study design Study
author
Country Study
year
Population Sample
size
Measurement method Drugs Adherence
RCT Bell [67] Malawi 2004-2006 >6 mo 841 Bioassay; self-report AL 100% SR 92.0%
MEMS
(questionnaire); MEMS* CPD 99.2% SR 90.6%
MEMS
SP 100% DOT
Dunyo [59] Gambia 2004 6mo - 10 yrs 1238 Pill Counts & self-report
(questionnaire)
AL 67.0%
CPD 94.0%
Faucher [60] Benin 2007 <5 yrs 240 Recovery of drug blisters AL 83.0%
AQAS 91.0%(pill-count)
SP 100%*
Achan [55] Uganda 2007/2008 6-59 mo 175 Pill Counts & care giver AL QNN 94.5% 85.4%
self-report (questionnaire)
Cross-sectional Ajayi [39] Ghana Uganda
Nigeria
2008** 6-59 mo 244 Self-report: AL Composite 94%
(timing, # doses, # of days) AQ + AS
Ajayi [40] Ghana Uganda
Nigeria
2008** 6-59 mo 1096 Self-report: AL Composite 85%
(timing, # doses, # of days) AQ + AS
Alba [41] Tanzania 2004-2008 All ages 32*** Self-report: AL 69.0%
(timing, # doses, # of days) SP 84.0%
QNN 0%
Composite 51.0%
*SR = Self-report; MEMS = Medical Event Monitoring System.
**In Ghana and Nigeria treatments were given at home unsupervised. In Uganda the first dose was administered as DOT.
***Information for AL was only available in the third survey conducted in 2008, so results presented are only from that survey.
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Factors associated with adherence to ACT
Demographic factors, such as sex, socio-economic status
or age were not significantly or consistently associated with
adherence [30,31,37,38,43,45-48,54,56,57,61-63]. However,
two studies did report a significant association between age
of the patient and the level of adherence [37,38]. Lawford
et al. found both the age of the respondent (caregiver) and
the age of the patient were significant factors associated
with adherence in Kenya. Older caregivers (between 25–
50 years of age) had 1.65 (95% CI = 1.10-1.85) the odds of
being fully adherent, compared to younger caregivers
(<25 years) [37]. The study also found that older patients
(15+ years) were more likely to be adherent compared to
those <15 years (OR = 1.37, 95% CI = 1.02-1.85). Mace
et al. also found that younger patients (<5 years of age)
in Malawi were less likely to be adherent to AL (OR =
0.05; 95% CI 0.3-0.8; p = 0.05) compared to older pa-
tients (18+ years) [38].
Education levels and literacy were both found to be sig-
nificantly associated with ACT adherence in five studies,
with higher levels of education and/or literacy positively
associated with adherence [30,31,48,56,57]. In Zanzibar,
Beer et al. reported that caretaker education (7+ years)
was a significant predictor of adherence (OR = 5.08; p =
0.008) [56]. In Zambia, patients whose caretakers had
some education had a significantly lower risk of non-
adherence (RR = 0.46, 95% CI = 0.22-0.95) [30]. Similarly,
in Uganda patients and/or caregivers that had attended at
least some secondary school were 22% more likely to be
adherent (p = 0.024) in one study [57] and in Uganda a
lack of caregiver formal education had a significant associ-
ation with non-adherence (OR 3.1, p = <0.05) [31]. An-
other study in Kenya found that higher education level
(OR = 0.074, p = <0.01) and the ability to read (OR =
0.285, p = < 0.01) were both positively associated with ad-
herence to ACT [48].
Language was also found to impact adherence. Care-
givers in Uganda that could read English were found to
have 0.47 fewer doses left compared to those that could
not read English (p = 0.024) [57]. Depoortere et al. found
that giving instructions on administration of treatment
to caregivers in their mother tongue lowered the risk of
non-adherence (RR = 0.46, 95% CI = 0.28 to 0.77). In
addition, patients given the first dose as directly ob-
served treatment (DOT) at the health centre were 2.4
times more likely to be adherent (p = 0.009) [30].
Patient/caregiver knowledge or understanding of treat-
ment dose was found to be a significant predictor of ad-
herence in two studies [37,63]. Patient preference or
dislike for a specific drug or ACT was found to be asso-
ciated with adherence in Kenya and Malawi [37,38]. And
Kalyango et al. found that some signs and symptoms of
patients such as no reported fever (OR = 3.3), caregivers’
perception that disease was not severe (OR = 2.0) and
vomiting (OR = 2.6) were all found to be associate with
non-adherence [63]. Achan also found that vomiting was
predictor of non-adherence (p = 0.02) [55].
Mace et al. found that caregivers receiving instructions
for treatment administration with a visual aide or medi-
cation package were slightly more likely to adhere to AL
in Malawi (OR = 2.5, p = 0.02) [38]. Other aspects that
have to do with taking or administering ACT, which
have been thought to improve adherence, such as pack-
aging doses together, providing pictorial instructions,
simplicity of dosage instructions and number of pills
were not prominent factors investigated. One study did
report that giving the exact number of tablets for the
prescribed dose was associated with adherence [56], sug-
gesting that pre-packaged doses should improve adher-
ence. Almost all of the patients in a Tanzanian study
reported that the pictogram printed on the packages and
the blister packaging depicting the correct treatment
Table 4 Studies that measure adherence to AS + SP
Study design Study author Country Study year Population Sample size Measurement method Adherence
Prospective observational Depoortere [30] Zambia 2002 6-59 mo 142 Pill counts & self-report
(questionnaire)
39.4%
RCT Kachur [62] Tanzania 2003 <5 128 Pill counts & self-report
(questionnaire) composite
75.0%
Table 5 Studies that measure adherence to AS +MQ
Study design Study author Country Study year Population Sample size Measurement method Adherence
Cross-sectional Yeung [54] Cambodia 2002 All ages 44 Self-report 77.0%
Prospective observational Congpuong [50] Thailand 2008/2009 All ages 240 Self-report & bioassay 96.3%
Meankaew [52] Thailand 2009 All ages 534 total; 285Pf Self-report 94.0%
Na-Bangchang [26] Thailand 1994/1995 All ages 126 Bioassay 98.1%*
Shwe [27] Myanmar 1996 All ages 380 Bioassay 99.5%**
*Full adherence reported; the majority of patients were adults.
**For both groups.
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doses were helpful, but the impact of this on adherence
was not assessed [36].
Discussion
Over the past decade substantial efforts have been made
to increase access and targeting of ACT for the effective
management of malaria. In order to ensure that effica-
cious drugs are also effective in routine heath care
systems, patient/caregiver adherence is important. This
review summarizes the current evidence base on ACT
adherence levels, adherence definitions and measure-
ment as well as factors associated with adherence
to ACT.
Adherence levels
ACT adherence levels varied, from less than <30% for
ACT in general in Kenya [53] and up to 100% adherence
to AL in Malawi [67]. The lack of homogeneity in find-
ings and the large range in adherence levels can be at-
tributed not only to the variability between study
settings, study designs and ACT formulations, but also
as a result of differences in study implementation such
as questionnaire/interviewing methods, blinding pa-
tients/caregivers to follow-up and study design features
(e.g. RCT vs. observational).
For example, the questionnaire used by Kabanywanyi
et al. to assess AL adherence in Kenya was semi-
structured with open-ended questions embedded within
the questionnaire [36]. Whereas the questionnaire used
by Lawford et al. (also looking at AL adherence in
Kenya) was more structured and resembled a malaria in-
dicator survey and thus collected a different type of data
[37]. Despite similar contexts and drug regimens, the
findings were different with one study finding adherence
to be only 64.1%, while the other found adherence to be
as high as 89.2%.
Ideally, standardized, comprehensive definitions and
measuring tools would be used to assess adherence, in-
cluding a definition which incorporates duration, timing
and frequency of dose. However, we found that this
comprehensive definition was only utilized for observa-
tional studies that looked at AL, a regimen requiring
multiple doses per day. In contrast, randomized con-
trolled trials (RCTs) looked primarily at whether the
drug was taken and not necessarily as to when or how it
was taken.
For certain ACT formulations, such as AL, timing is
important to the overall effectiveness of the regimen and
should, therefore, be taken into account when determin-
ing adherence levels. From a public health perspective, a
more synchronized evidence base on how and when pa-
tients take ACT can lead to more patient friendly pack-
aging and dosing instructions. Therefore, a standardized
definition of adherence would be useful to enable com-
parison between ACT regimens as well as to help iden-
tify contextual trends.
Factors associated with adherence
Little is known with regard to the determinants of ad-
herence to ACT. Findings and trends were not consist-
ent across studies. Demographic factors, such as sex,
socio-economic status or age do not seem to be factors
strongly or consistently associated with adherence
[30,31,37,38,43,45-48,54,56,57,61-63]. However, it is im-
portant to note that some studies were not actually repre-
sentative and/or powered to look at age groups. Two
studies did find a significant association between age of
the patient and the level of adherence, both suggesting
that younger patients were less likely to be adherent. In
Malawi, children less than five were less adherent than
older children [38]; while in Kenya patients less than 15
years of age were less adherent than older patients [37].
Previously, age has been reported as a risk factor for
poor adherence to non-ACT regimens [16], suggesting
that age related factors should be considered when de-
veloping anti-malarial regimens and communication
campaigns. Vomiting has also been found to be nega-
tively associated with adherence to both AQ + AS and
AL [61,63], however it was also considered as exclu-
sion criteria for some studies or not accounted for
when defining adherence in others. As vomiting can be
influenced by severity of disease as well as treatment
regimen and patient/caregiver behaviour after vomiting
is influenced by knowledge provided by health workers,
care should be taken when attributing non-adherence to
vomiting. Further investigations surrounding vomiting
and related factors and the impact on adherence is
warranted.
Study designs
As adherence is difficult to measure accurately retro-
spectively, the majority of studies (17) were found to be
prospective observational studies. Although many of
these were similar in design, differences in context and
study regimes made direct comparisons challenging and
precluded data synthesis.
Table 6 Studies that measure adherence to unspecified ACT combinations
Study design Study author Country Study year Population Sample size Measurement method Adherence
Cross-sectional Onyango [48] Kenya 2012* <13 297 Self-report 47.0%
Watsierah [53] Kenya 2011* <13 397 Self-report 29.4% dose 33.0% duration
*Publication year used as year of study unknown.
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Cross-sectional household surveys [40,70] and effect-
iveness studies [45,55,59,60,67], reported higher levels of
adherence, however this can be attributed to the study
design. In the cross-sectional surveys, adherence ques-
tions are asked retrospectively; patients or caregivers
were asked to recall how they took or gave the ACT.
Cross-sectional surveys are vulnerable to recall bias, par-
ticularly as the time frame for recall is often two or more
weeks after receiving treatment, and thus may over- or
underestimate adherence levels.
Furthermore, cross-sectional household surveys, which
are often influenced by the Roll Back Malaria (RBM),
Malaria Indicator Survey (MIS), focus primarily on the
treatment seeking process and not on how one particu-
lar regimen was taken (dose & timing), thus offering an
indication of adherence, but not an exact measurement.
Additionally, patient knowledge or recognition of the
drugs may not be sufficient through these types of surveys.
Likewise, differences in nomenclature may play a large
role in understanding the survey questions, whereby the
study researchers may use the actual drug names; respon-
dents may use local names to describe the same medica-
tion. To address this, one study carried out in Kenya
made treatment charts with examples of drugs to assist re-
spondents with their recall [48], however this was not the
norm.
Prospective observational studies that interviewed pa-
tients or caregivers the day following the last treatment,
should have better recall, however, the accuracy of the
measurement is dependent on how patients/caregivers
were recruited and whether they knew they would be
followed up at a later date. In studies like that of Cohen
et al. and Gerstl et al. where patients were blinded to
potential follow-up, adherence levels were lower than
other studies [57,61]. Souares et al. found similar results
in Senegal, where patients were also blinded to follow-
up visits after receiving treatment for amodiaquine plus
sulphadoxine-pyrimethamine (AQ + SP), and reported
an adherence rate of 64.7% [16]. Therefore, one could
consider that participants that were aware of future
follow-up visits at the time of recruitment may adhere
better than those that do not.
Effectiveness study designs (RCT and pre-post designs)
have similar challenges, as patients are enrolled and con-
sent to participation prior to taking part in the study. In
the majority of studies, patients/caregivers knew that
they were enrolled in a study and therefore may have al-
tered their behaviour to be more favourable (i.e. Hawthorn
effect).
Methods of measuring ACT adherence
Although studies on adherence to anti-malarials have
been conducted for over a decade, methodologies and
definitions of adherence still lack standardization. In a
number of studies the definition for adherence was cate-
gorized as; probably adherent, probably non-adherent
and non-adherent. This approach to defining adherence
is crude and imprecise and may lead to an individual’s
adherence status being misclassified resulting in an over-
or underestimation of adherence.
Most of the methods used to measure adherence to
anti-malarials were developed measuring non-ACT for-
mulations [10], yet they are still widely used to measure
adherence to ACT today. However, many of the current
measurement methods used are suboptimal as malaria is
typically found in countries with limited resources where
patients often live in remote or hard to reach areas,
which makes follow-up difficult and biological assays
impractical.
Currently questionnaires for ACT adherence are not
standardized and follow more complex household survey
structures similar to the RBM malaria indicator survey
and demographic and health surveys. For both HIV and
TB treatment regimens standardized questionnaires have
been used to assess treatment adherence. Some ques-
tionnaires are long and detailed (e.g. AIDS Clinical Tri-
als Group adherence questionnaire), while others are
short or abbreviated versions, which can be used during
patient consultations and still provide a relatively accur-
ate adherence measurement (e.g. the Brief Medical
Questionnaire (BMQ) and Morisky Scale) [71-73]. Al-
though questionnaires utilized for chronic disease medi-
cation adherence are not directly translatable to acute
illnesses such as malaria, the idea of a short and standard-
ized questionnaire that can be easily implemented in low
resource settings would make it easier to routinely assess
adherence to ACT.
Although measuring adherence through self-report is
operationally less expensive and easier to implement, it is
subject to social desirability bias, which may overestimate
adherence. Study designs should take this into account by
blinding patients/caregivers to potential follow-up visits as
well as asking about medication intake in different ways
during the interviews. MEMS and biological assays are
more objective methods to measure adherence and may
offer more precise adherence measurements, however
they can both be costly and biological assays may not be
possible for all ACT combinations. Furthermore, MEMS
strategies may alter packaging, which may impact the way
in which patients consume medications [9,13,14].
Further consensus is needed with regard to translating bio-
assay data into a measurement of adherence/non-adherence.
Studies in this review found that biological assays were pri-
marily incorporated into effectiveness studies looking at su-
pervised versus unsupervised administration AL treatment
with the purpose of validating whether the patient had
ingested the medication. Although this method is itself ob-
jective in terms of measuring drug metabolites in the blood,
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interpretation of the results can be problematic. Absorption
levels for lumefantrine are known to be variable due to sub-
optimal absorption with low fat intake [68,74,75]. None of
the studies collected information on fat intake at the time of
assessing adherence, thus this method may underestimate
adherence levels.
Only three studies compared day-7 lumefantrine blood
levels between adherent and non-adherent patients, but
no study found a significant difference between the two
groups [31,45,46]. Furthermore, all three studies had
limited numbers of patients that were non-adherent,
thus limiting their power to detect differences. For bio-
assays to be a viable method for measuring adherence to
AL, additional studies with larger samples may be needed
in order to determine if there is a correlation between
blood lumefantrine levels and adherence status.
Limitations of the review
This review has several limitations. First, information on
adherence to ACT is often a secondary outcome embed-
ded into larger studies, and details on the measurement
of adherence outcomes are often missing or not re-
ported. As a result, studies with limited information on
adherence may have been missed or excluded. Second,
this review was limited to peer-reviewed publications. As
adherence can be considered an operational issue, much
of the data collected on ACT in developing countries
may be unpublished. Third, the majority of studies re-
garding ACT adherence (~60%) have been conducted in
East or Southern Africa and the range of ACT formula-
tions studied was narrow, with over half of the studies
looking primarily at adherence to AL. Only seven studies
compared adherences levels between ACT formulations,
thus lacking critical information that may improve ac-
cess and targeting ACT and inform policy decision-
making. Fourth, as the studies were conducted in a
variety of countries with different ACT combinations,
amongst different age groups and populations, in dif-
ferent settings with different methods and sample
sizes, direct comparisons of ACT adherence levels
should be reviewed with caution. However, trends in
adherence levels and associated factors can be noted
and further explored. Finally, as adherence may be influ-
enced by cultural and contextual factors, this review pro-
vides only a narrow picture of how ACT is taken and
further qualitative investigations should be considered.
Conclusions
This review highlights the weak evidence base on ACT
adherence. Results suggest that ACT adherence levels
varied substantially between study populations and com-
parison between studies was challenging due to differ-
ences in study design, definitions, and methods used to
measure adherence. Standardising methodologies for
both self-report and bioassays used for evaluating adher-
ence of different formulations across diverse contexts
would improve the evidence base on ACT adherence and
effectiveness; namely, specific and measurable definitions
for adherence are needed for both methodologies.
Additionally, further studies of the individual factors
and barriers associated with non-adherence to ACT
are needed in order to make informed policy choices
and to improve the delivery of effective malaria treatment.
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